RNA interference and its potential applications to chronic HBV treatment: Results of a Phase I safety and tolerability study

Antiviral Therapy

Volumn 16, Issue 4, 2011, Pages 547-554

  Gish, Robert G ^a   Satishchandran, C ^b   Young, Michael ^c   Pachuk, Catherine ^d  

^a UCSD MEDICAL CENTER   (United States)

^b NORTH DAKOTA STATE UNIVERSITY   (United States)

^c MDY Associates LLC   (United States)

^d PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANTIPYRETIC AGENT; ANTIRETROVIRUS AGENT; CHOLESTERYL SPERMINE; ENTECAVIR; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 18; INTERLEUKIN 6; INTERLEUKIN 8; NANOPARTICLE; NUC B 1000; PLASMID VECTOR; SHORT HAIRPIN RNA; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ADULT; AGED; ANTIVIRAL ACTIVITY; ARTICLE; CASE REPORT; CHILL; COHORT ANALYSIS; CYTOKINE RELEASE; DISEASE SEVERITY; DRUG DOSE ESCALATION; DRUG FEVER; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; GENE SILENCING; GENE TARGETING; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; IN VITRO STUDY; IN VIVO STUDY; MALE; MYALGIA; NAUSEA; NONHUMAN; NOSE CONGESTION; PHARYNGITIS; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RNA INTERFERENCE; SIDE EFFECT; SINGLE DRUG DOSE; TARGET CELL; THROAT IRRITATION; TREATMENT DURATION;

ADULT; ANTIVIRAL AGENTS; CYTOKINES; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; MALE; MIDDLE AGED; RNA INTERFERENCE; RNA, SMALL INTERFERING; TREATMENT OUTCOME;

EID: 79959466157     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: 10.3851/IMP1798     Document Type: Article

References (17)

1. Hajeri PB, Singh SK. siRNAs: their potential as therapeutic agents - Part I. Designing of siRNAs. Drug Discov Today 2009; 14:851-858.
2. Singh SK, Hajeri PB. siRNAs: their potential as therapeutic agents - Part II. Methods of delivery. Drug Discov Today 2009; 14:859-865.
3. Stevenson M. Therapeutic potential of RNA interference. N Engl J Med 2004; 351:1772-1777.
4. Lee RC, Feinbaum RL, Ambros V. The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell 1993; 75:843-854. (Pubitemid 24014542)
5. Fire A, Xu S, Montgomery MK, et al. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 1998; 391:806-811. (Pubitemid 28099681)
6. Grimm D, Streetz KL, Jopling CL, et al. Fatality in mice due to oversaturation of cellular microRNA/short hairpin RNA pathways. Nature 2006; 441:537-541. (Pubitemid 44050158)
7. Guo S, Kemphues KJ. Molecular genetics of asymmetric cleavage in the early Caenorhabditis elegans embryo. Curr Opin Genet Dev 1996; 6:408-415. (Pubitemid 26280792)
8. Napoli C, Lemieux C, Jorgensen R. Introduction of a chimeric chalcone synthase gene into petunia results in reversible co-suppression of homologous genes in trans. Plant Cell 1990; 2:279-289. (Pubitemid 120029588)
9. Recombinant DNA Advisory Committee (RAC). 2006 Past RAC meetings. Office of Biotechnology Activities. 2006. National Institutes of Health. (Updated 27 October 2010. Accessed 28 August 2009.) Available from http://oba.od.nih.gov/ rdna/rac-past-meeting-2006-webcasts.html#dec06, http://oba.od.nih.gov/rdna-rac/ rac-past-meetings-2000.html#RAC2006
10. Winston WM, Molodowitch C, Hunter CP. Systemic RNAi in C. elegans requires the putative transmembrane protein SID-1. Science 2002; 295:2456-2459. (Pubitemid 34270260)
11. Wolfrum C, Shi S, Jayaprakash KN, et al. Mechanisms and optimization of in vivo delivery of lipophilic siRNAs. Nat Biotechnol 2007; 25:1149-1157. (Pubitemid 47538115)
12. Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology 2007; 45:507-539. (Pubitemid 46374607)
13. US Food and Drug Administration, Department of Health and Human Services. Adverse event reporting system (AERS). (Updated 20 August 2009. Accessed 25 October 2010.) Available from http://www.fda.gov/Drugs/ GuidanceComplianceRegulatoryInformation/Surveillance/AdverseDrugEffects/default. htm
14. Sioud M. Induction of inflammatory cytokines and interferon responses by double-stranded and single-stranded siRNAs is sequence-dependent and requires endosomal localization. J Mol Biol 2005; 348:1079-1090. (Pubitemid 40602367)
15. Chang JJ, Thompson AJ, Visvanathan K, et al. The phenotype of hepatitis B virus-specific T cells differ in the liver and blood in chronic hepatitis B virus infection. Hepatology 2007; 46:1332-1340. (Pubitemid 350155514)
16. Kanzler H, Barrat FJ, Hessel EM, Coffman RL. Therapeutic targeting of innate immunity with Toll-like receptor agonists and antagonists. Nat Med 2007; 13:552-559 (Pubitemid 46830615)
17. + progenitor cells can avoid induction of interferon responses to siRNAs in vitro. Nat Biotechnol 2006; 24:566-571.